These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6619048)

  • 21. [Pharmacokinetics of temocillin after intravenous and intramuscular administration].
    Modr Z; Dvorácek K; Morávek J; Sechser T; Janků I; Krebs V
    Cas Lek Cesk; 1985 Dec; 124(49):1522-5. PubMed ID: 4084955
    [No Abstract]   [Full Text] [Related]  

  • 22. Temocillin concentrations in human tissues.
    Gould JG; Meikle G; Cooper DL; Horton R
    Drugs; 1985; 29 Suppl 5():167-70. PubMed ID: 3928320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The penetration of amoxycillin/clavulanic acid into peritoneal fluid.
    Wise R; Donovan IA; Drumm J; Andrews JM; Stephenson P
    J Antimicrob Chemother; 1983 Jan; 11(1):57-60. PubMed ID: 6826486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biliary concentrations of temocillin.
    Spelsberg F; Bauernfeind A; Wiest W; Hanser P
    Drugs; 1985; 29 Suppl 5():122-7. PubMed ID: 4029015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antibiotic concentrations in the abdominal cavity as basis for antibacterial therapy of peritonitis: penetration of mezlocillin into the peritoneal exudate].
    Wittmann DH; Welter J; Schassan HH
    Infection; 1982; 10 Suppl 3():S204-8. PubMed ID: 6218115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
    De Jongh R; Hens R; Basma V; Mouton JW; Tulkens PM; Carryn S
    J Antimicrob Chemother; 2008 Feb; 61(2):382-8. PubMed ID: 18070831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vancomycin pharmacokinetics in patients undergoing chronic intermittent peritoneal dialysis.
    Glew RH; Pavuk RA; Shuster A; Alfred HJ
    Int J Clin Pharmacol Ther Toxicol; 1982 Dec; 20(12):559-63. PubMed ID: 7152738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of renal function and dialysis on temocillin pharmacokinetics.
    Boelaert J; Daneels R; Schurgers M; Mellows G; Swaisland AJ; Lambert AM; Van Landuyt HW
    Drugs; 1985; 29 Suppl 5():109-13. PubMed ID: 4029012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of temocillin in volunteers.
    Hampel B; Feike M; Koeppe P; Lode H
    Drugs; 1985; 29 Suppl 5():99-102. PubMed ID: 4029032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration.
    Laterre PF; Wittebole X; Van de Velde S; Muller AE; Mouton JW; Carryn S; Tulkens PM; Dugernier T
    J Antimicrob Chemother; 2015 Mar; 70(3):891-8. PubMed ID: 25433006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential role of temocillin in the treatment of biliary sepsis.
    Uwaydah M; Vartivarian S; Harakeh H; Awdeh A; Najjar F
    Drugs; 1985; 29 Suppl 5():186-90. PubMed ID: 4029024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of temocillin (BRL 17421) in subjects with normal and impaired renal function.
    Leroy A; Humbert G; Fillastre JP; Borsa F; Godin M
    J Antimicrob Chemother; 1983 Jul; 12(1):47-58. PubMed ID: 6619046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic experience with temocillin in peritonitis.
    Pfeiffer M; Fock RR
    Drugs; 1985; 29 Suppl 5():194-6. PubMed ID: 3896740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrice-weekly temocillin administered after each dialysis session is appropriate for the treatment of serious Gram-negative infections in haemodialysis patients.
    Vandecasteele SJ; Miranda Bastos AC; Capron A; Spinewine A; Tulkens PM; Van Bambeke F
    Int J Antimicrob Agents; 2015 Dec; 46(6):660-5. PubMed ID: 26603304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraperitoneal penetration of meropenem.
    Hextall A; Andrews JM; Donovan IA; Wise R
    J Antimicrob Chemother; 1991 Aug; 28(2):314-6. PubMed ID: 1778863
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice.
    Shimada T; Nomura M; Yokogawa K; Endo Y; Sasaki T; Miyamoto K; Yonemura Y
    J Pharm Pharmacol; 2005 Feb; 57(2):177-81. PubMed ID: 15720780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy, tolerance and pharmacokinetics of temocillin in patients with respiratory tract infections.
    Legge JS; Reid TM; Palmer JB
    Drugs; 1985; 29 Suppl 5():118-21. PubMed ID: 4029014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model.
    Pestieau SR; Stuart OA; Sugarbaker PH
    Eur J Surg Oncol; 2000 Nov; 26(7):696-700. PubMed ID: 11078617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The penetration of cefoxitin into peritoneal fluid.
    Wise R; Donovan IA; Ambrose NS; Allcock JE
    J Antimicrob Chemother; 1981 Dec; 8(6):453-7. PubMed ID: 7333989
    [No Abstract]   [Full Text] [Related]  

  • 40. Temocillin pharmacokinetics in normal and impaired renal function.
    Höffler D; Koeppe P
    Drugs; 1985; 29 Suppl 5():135-9. PubMed ID: 4029017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.